Core Viewpoint - Zhejiang Zhenyuan has decided to terminate its plan for a private placement of shares originally intended to raise 495 million yuan due to the current capital market environment and the company's overall development strategy [1][4]. Group 1: Fundraising and Project Details - The company initially aimed to raise 495 million yuan to focus on core pharmaceutical industrial projects, including the raw material drug aggregation enhancement project and the Shangyu industrialization base project [2]. - The raw material drug aggregation enhancement project has a total investment of 481 million yuan, with 195 million yuan planned to be raised from the issuance. It is designed to have an annual production capacity of 436 tons and is expected to generate annual sales revenue of 565 million yuan and a net profit of 124 million yuan upon full production [2][3]. - The Shangyu industrialization base project has a total investment of 587 million yuan, with 300 million yuan planned to be raised. It aims to produce 2,400 tons of histidine and other products, with expected annual sales revenue of 624 million yuan and a net profit of 179 million yuan upon completion [3]. Group 2: Project Progress and Financial Status - Both projects are currently under construction and have not been affected by the termination of the share issuance. The raw material drug aggregation enhancement project has a construction progress of 40%, while the Shangyu industrialization base project has reached 95% completion [4][5]. - As of June 30, the company reported a cash balance of 513 million yuan, indicating sufficient liquidity despite a slight decrease from the end of 2024. The overall debt level remains manageable, with short-term borrowings of 20.08 million yuan and long-term borrowings of 169 million yuan [4].

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

Core Viewpoint - Zhejiang Zhenyuan has decided to terminate its plan to issue shares to specific investors and has withdrawn its application due to considerations of the current capital market environment and the company's overall development strategy [1][2]. Group 1: Termination of Share Issuance - The company held a board meeting on October 21, 2025, where it approved the decision to terminate the share issuance and withdraw the application [1]. - The termination decision was made after thorough communication and analysis with relevant parties, considering the current capital market conditions [2]. Group 2: Financial Implications - The company stated that the termination of the share issuance will not adversely affect its normal production and operations, nor will it harm the interests of shareholders, especially minority shareholders [2]. - The planned fundraising amount was up to 49,500 million CNY, intended for specific projects including the construction of a production base for various biochemical products and an enhancement project for raw materials [2][3]. Group 3: Project Details - The projects intended for the raised funds included: 1. Construction of a production base for 2,400 tons of histidine, 1,000 tons of levodopa, and 1,000 tons of tyrosine, with a total investment of approximately 58.70 million CNY and planned fundraising of 30 million CNY [3]. 2. A project for enhancing raw material production with a total investment of about 48.12 million CNY and planned fundraising of 19.50 million CNY [3]. - The total investment for both projects was approximately 106.83 million CNY, with a total planned fundraising of 49.50 million CNY [3].

Group 1 - The company, Zhejiang Zhenyuan, announced the termination of its plan to issue stocks to specific investors and will withdraw the application documents [2] - The decision was made during the fourth temporary meeting of the 11th Board of Directors and the first temporary meeting of the 11th Supervisory Board, held on October 21, 2025 [2] - This marks a significant shift in the company's financing strategy, indicating a potential reevaluation of its capital needs [2]

Core Viewpoint - Zhejiang Zhenyuan announced the termination of its plan to issue stocks to specific investors and the withdrawal of related application documents [1] Company Summary - Zhejiang Zhenyuan held its 11th Board of Directors' fourth temporary meeting and the 11th Supervisory Board's first temporary meeting on October 21, 2025, where the decision to terminate the stock issuance was made [1]

Core Viewpoint - Zhejiang Zhenyuan (000705) has decided to terminate the issuance of shares to specific targets, citing the current capital market environment and the company's overall development plan as key factors [1] Group 1 - The company has communicated and analyzed the situation with relevant parties before making the decision to withdraw the application for the issuance of shares [1] - Following the termination of the share issuance, the company plans to utilize its own and self-raised funds to ensure the smooth implementation of fundraising projects [1]

证券代码：000705 证券简称：浙江震元 公告编号：2025-039 浙江震元股份有限公司第十一届监事会 2025 年第一次临时会议决议公告 浙江震元第十一届监事会 2025 年第一次临时会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江震元股份有限公司第十一届监事会 2025 年第一次临时会议通知于 2025 年 10 月 17 日以电话形式通知，2025 年 10 月 21 日以通讯形式召开。本次会议应 出具表决意见监事 4 人，实际出具表决意见监事 4 人，会议的召开符合有关法律、 行政法规、部门规章、规范性文件和公司章程的规定。 二、监事会会议审议情况 1、审议通过《关于公司终止向特定对象发行股票事项并撤回申请文件的议案》。 表决结果：4 票同意，0 票反对，0 票弃权。 监事会认为：公司终止向特定对象发行股票事项的审议程序符合《公司法》《证 券法》等有关法律、法规以及《公司章程》的规定。该事项不会对公司的正常业 务经营产生重大不利影响，不存在损害公司及全体股东、特别是中小股东利益的 情形。 三、备查文件 浙江 ...

浙江震元第十一届董事会 2025 年第四次临时会议决议公告 1、审议通过《关于公司终止向特定对象发行股票事项并撤回申请 文件的议案》。 自公司披露本次向特定对象发行股票事项以来，公司与相关中介 机构积极推进各项工作。现综合考虑当前资本市场环境以及公司整体 发展规划等因素，经与相关各方充分沟通、审慎分析后，公司决定终 止本次向特定对象发行股票事项，并主动向深圳证券交易所申请撤回 相关申请文件。 具体详见同日披露于巨潮资讯网（http://www.cninfo.com.cn） 的《关于公司终止向特定对象发行股票事项并撤回申请文件的公告》 （公告编号：2025-038）。 1 证券代码：000705 证券简称：浙江震元 公告编号：2025-037 浙江震元股份有限公司第十一届董事会 2025年第四次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江震元股份有限公司第十一届董事会2025年第四次临时会议通 知于 2025 年 10 月 17 日以书面、通讯等形式发出，2025 年 10 月 21 日以通讯形式召开。会议应以通 ...

Core Viewpoint - Zhejiang Zhenyuan (000705.SZ) has decided to terminate its plan for a private placement of shares due to considerations of the current capital market environment and the company's overall development strategy [1] Group 1 - The company has actively engaged with relevant intermediaries to advance the issuance process since announcing the private placement [1] - After thorough communication and careful analysis with all parties involved, the company has opted to withdraw its application for the private placement from the Shenzhen Stock Exchange [1]

Core Viewpoint - Zhejiang Zhenyuan (000705.SZ) has decided to terminate its plan for a private placement of shares due to considerations of the current capital market environment and the company's overall development strategy [1] Group 1 - The company has actively engaged with relevant intermediaries to advance the issuance process since announcing the private placement [1] - After thorough communication and careful analysis with all parties involved, the company has opted to withdraw its application for the private placement from the Shenzhen Stock Exchange [1]